Natural killer cell activity in patients with hepatocellular carcinoma
Akinobu Taketomi(Hokkaido University), Keizō Sugimachi(Kyushu University), Ken Shirabe(Gunma University), Mitsuo Shimada(Tokushima University), Tomonobu Gion(Kyushu University), Kiyoshi Kajiyama(Kyushu University)
Cited by 136
Related Papers
Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH‐HCC guidelines) 2019 update
|Hepatology Research|2019|539
Randomized clinical trial of adjuvant gemcitabine chemotherapy <i>versus</i> observation in resected bile duct cancer
|British journal of surgery|2018|401
Interleukin‐6/<scp>STAT</scp>3 signaling as a promising target to improve the efficacy of cancer immunotherapy
|Cancer Science|2017|295
Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH‐HCC Guidelines)
|Hepatology Research|2023|281
Genome-wide Association Study Identifies TNFSF15 and POU2AF1 as Susceptibility Loci for Primary Biliary Cirrhosis in the Japanese Population
|The American Journal of Human Genetics|2012|272